AOC 1044 delivered up to 50-times greater concentrations of PMO in skeletal muscle following a single dose compared to peptide conjugated PMOs in healthy volunteers AOC 1044 was well tolerated, ...
Volume 7 of investor and analyst event today at 5:30 p.m. ET in Boston and via webcast "The AOC 1001 topline data demonstrated directional improvement across a variety of functional assessments in ...
Avidity Biosciences, Inc. (NASDAQ:RNA) is developing a new class of RNA-based therapies called Antibody Oligonucleotide Conjugates (AOCs). These therapies aim to treat rare muscle disorders like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback